By Dr Joanna Achinger-Kawecka

Journal articles

Peters TJ; Meyer B; Ryan L; Achinger-Kawecka J; Song J; Campbell EM; Qu W; Nair S; Loi-Luu P; Stricker P; Lim E; Stirzaker C; Clark SJ; Pidsley R, 2024, 'Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling', BMC Genomics, 25, http://dx.doi.org/10.1186/s12864-024-10027-5

Chen W; Zeng YC; Achinger-Kawecka J; Campbell E; Jones AK; Stewart AG; Khoury A; Clark SJ, 2024, 'Machine learning enables pan-cancer identification of mutational hotspots at persistent CTCF binding sites', Nucleic Acids Research, 52, pp. 8086 - 8099, http://dx.doi.org/10.1093/nar/gkae530

Tian L; Jiao X; Wang C; Ertel A; Soccio R; Chen ER; Győrffy B; Sante GD; Zhong Z; Addya S; McCue PA; Kossenkov AV; Achinger-Kawecka J; Clark S; Pestell RG, 2024, 'Abstract 3582: PPAR gamma acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding', Cancer Research, 84, pp. 3582 - 3582, http://dx.doi.org/10.1158/1538-7445.am2024-3582

Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia KM; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Chen W; Pidsley R; Qu W; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ, 2024, 'The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer', Nature Structural and Molecular Biology, 31, pp. 498 - 512, http://dx.doi.org/10.1038/s41594-023-01181-7

Achinger-Kawecka J; Correa S; Hu J; Li G; Lindeboom RGH; Misale S; Monkkonen T; Nirmal AJ; Prekovic S; Sinha S; Trigos AS; Watson CJ, 2023, 'The 2023 generation', Nature Cancer, 4, pp. 1630 - 1635, http://dx.doi.org/10.1038/s43018-023-00681-1

Hastings JF; Latham SL; Kamili A; Wheatley MS; Han JZR; Wong-Erasmus M; Phimmachanh M; Nobis M; Pantarelli C; Cadell AL; O’Donnell YEI; Leong KH; Lynn S; Geng FS; Cui L; Yan S; Achinger-Kawecka J; Stirzaker C; Norris MD; Haber M; Trahair TN; Speleman F; De Preter K; Cowley MJ; Bogdanovic O; Timpson P; Cox TR; Kolch W; Fletcher JI; Fey D; Croucher DR, 2023, 'Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.abp8314

Brown LJ; Achinger-Kawecka J; Portman N; Clark S; Stirzaker C; Lim E, 2022, 'Epigenetic Therapies and Biomarkers in Breast Cancer', Cancers, 14, http://dx.doi.org/10.3390/cancers14030474

Giles KA; Gould CM; Achinger-Kawecka J; Page SG; Kafer GR; Rogers S; Luu PL; Cesare AJ; Clark SJ; Taberlay PC, 2021, 'BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer', Clinical Epigenetics, 13, http://dx.doi.org/10.1186/s13148-021-01023-7

Du Q; Smith GC; Luu PL; Ferguson JM; Armstrong NJ; Caldon CE; Campbell EM; Nair SS; Zotenko E; Gould CM; Buckley M; Chia KM; Portman N; Lim E; Kaczorowski D; Chan CL; Barton K; Deveson IW; Smith MA; Powell JE; Skvortsova K; Stirzaker C; Achinger-Kawecka J; Clark SJ, 2021, 'DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity', Cell Reports, 36, http://dx.doi.org/10.1016/j.celrep.2021.109722

Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia K-M; Du Q; Laven-Law G; Nair S; Yong A; Wilkinson A; Clifton S; Milioli H; Alexandrou S; Caldon E; Song J; Khoury A; Meyer B; Gee JMW; Schmitt A; Wong E; Hickey T; Lim E; Clark S, 2021, 'Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer', , http://dx.doi.org/10.1101/2021.06.21.449340

Khoury A; Achinger-Kawecka J; Bert SA; Smith GC; French HJ; Luu PL; Peters TJ; Du Q; Parry AJ; Valdes-Mora F; Taberlay PC; Stirzaker C; Statham AL; Clark SJ, 2020, 'Constitutively bound CTCF sites maintain 3D chromatin architecture and long-range epigenetically regulated domains', Nature Communications, 11, http://dx.doi.org/10.1038/s41467-019-13753-7

Achinger-Kawecka J; Valdes-Mora F; Luu PL; Giles KA; Caldon CE; Qu W; Nair S; Soto S; Locke WJ; Yeo-Teh NS; Gould CM; Du Q; Smith GC; Ramos IR; Fernandez KF; Hoon DS; Gee JMW; Stirzaker C; Clark SJ; Valdes Mora F, 2020, 'Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer', Nature Communications, 11, pp. 320, http://dx.doi.org/10.1038/s41467-019-14098-x

Giles KA; Gould CM; Achinger-Kawecka J; Page SG; Kafer G; Luu P-L; Cesare AJ; Clark SJ; Taberlay PC, 2020, 'BRG1 promotes transcriptional patterns that are permissive to proliferation in cancer cells', , http://dx.doi.org/10.1101/2020.07.03.187385

Giles KA; Gould CM; Du Q; Skvortsova K; Song JZ; Maddugoda MP; Achinger-Kawecka J; Stirzaker C; Clark SJ; Taberlay PC, 2019, 'Integrated epigenomic analysis stratifies chromatin remodellers into distinct functional groups', Epigenetics and Chromatin, 12, http://dx.doi.org/10.1186/s13072-019-0258-9

Fuksiewicz M; Kotowicz B; Rutkowski A; Achinger-Kawecka J; Wagrodzki M; Kowalska MM, 2018, 'The assessment of clinical usage and prognostic value of YKL-40 serum levels in patients with rectal cancer without distant metastasis', Technology in Cancer Research and Treatment, 17, http://dx.doi.org/10.1177/1533033818765209

Achinger-Kawecka J; Clark SJ, 2017, 'Disruption of the 3D cancer genome blueprint', Epigenomics, 9, pp. 47 - 55, http://dx.doi.org/10.2217/epi-2016-0111

Achinger-Kawecka J; Taberlay PC; Clark SJ, 2016, 'Alterations in three-dimensional organization of the cancer genome and epigenome', Cold Spring Harbor Symposia on Quantitative Biology, 81, pp. 41 - 51, http://dx.doi.org/10.1101/sqb.2016.81.031013

Taberlay PC; Achinger-Kawecka J; Lun ATL; Buske FA; Sabir KS; Gould CM; Zotenko E; Bert SA; Giles KA; Bauer D; Smyth GK; Stirzaker C; O Donoghue SI; Clark SJ, 2016, 'Three-dimensional disorganisation of the cancer genome occurs coincident with long range genetic and epigenetic alterations', Genome Research, 26, pp. 719 - 731

Hoppe R; Achinger-Kawecka J; Winter S; Fritz P; Lo WY; Schroth W; Brauch H, 2013, 'Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment', European Journal of Cancer, 49, pp. 3598 - 3608, http://dx.doi.org/10.1016/j.ejca.2013.07.145

Back to profile page